OUR Commitment to NEUROPSYCHIATRIC, NEURODEGENERATIVE AND NEUROLOGICAL CONDITIONS
Thank you for visiting the Janssen Neuroscience R&D Newsroom!
Below, please find our meeting news, social feeds, and more information about our progress and commitment to developing innovative medicines for neuropsychiatric, neurodegenerative, and neurological conditions, including depression, multiple sclerosis, Alzheimer's and more.
The Janssen Research & Development Neuroscience team is focused on neurodegenerative disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease; neurological/neuromuscular diseases, such as myasthenia gravis and epilepsy; and neuropsychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, and autism. Despite several advancements in neuroscience over the past 60 years, unmet need persists for patients across a broad range of these kinds of disorders. However, there has been significant progress in understanding and treating these diseases, and at Janssen, we never stop pushing the boundaries of what is possible.